white → pink1 → red1
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
4-FMA
4-Fluoromethamphetamine
para-Fluoromethamphetamine
4-FMA is a novel stimulant-entactogen of the substituted amphetamine class, chemically related to both methamphetamine and 4-fluoroamphetamine. First detected in Japanese legal high markets in 2006, it gained wider popularity as a research chemical after 4-FA was banned in the Netherlands in 2017.citation needed User reports describe its effects as combining traditional stimulant and entactogenic qualities, subjectively situated between 4-FA and 2-FMA. Little is known about its pharmacology or toxicology.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~15 mg
Light15-50 mg
Moderate50-75 mg
Strong75-125 mg
Heavy125+ mg
Duration
Onset20-40 minutes
Come Up20-40 minutes
Peak2-5 hours
Offset1-2 hours
After Effects3-12 hours
Total4-8 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
4-FMA produces a stimulating experience broadly comparable to other substituted amphetamines, characterized by euphoria, mood lift, and a marked increase in energy and alertness. Users become notably more sociable and talkative, with heightened sexuality also reported. The experience carries a distinctly stimulant-typical profile in which wakefulness persists well beyond the desired duration, and at heavier use hallucinations, aggressiveness, and mood instability can emerge.
Physical
The body load is that of a typical stimulant: increased energy, decreased appetite, and a reduced need for sleep, accompanied by sweating, jaw tension, itchiness, and disturbed sleep patterns after the experience ends.
Uncomfortable
Cognitive
The headspace is energetic and socially disinhibited, marked by mood lift, euphoria, and excessive talking. This can shift toward moodiness and aggressiveness, especially as the experience progresses or with repeated dosing.
Emotional
Enhancements
Visual
Visual effects are largely absent at typical doses, though hallucinations have been reported with heavy use.
Auditory
Pharmacology
Pharmacodynamics
4-FMA is thought to act as a releasing agent and reuptake inhibitor of serotonin, dopamine, and norepinephrine.citation needed It binds to and partially blocks the monoamine transporter proteins, increasing the synaptic concentration of all three neurotransmitters. Relatively little formal pharmacological research has been conducted on 4-FMA, and its proposed mechanism is largely inferred from its structural relationship to other fluorinated amphetamines.
Pharmacokinetics
Very little is known about the metabolism of 4-FMA. It has been identified as a CYP450 enzyme inhibitor, a property that has been shown to reduce the metabolism of methamphetamine when the two are present together.citation needed
Metabolitesnone documented yet
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Many effects can become less responsive after prolonged repeated use, leading users to need higher doses for similar results.
Baseline Reset
1-2 weeks for stimulant effects; tolerance to entactogenic effects may take longer to return to baseline.
Half Tolerance
3-7 days
Cross Tolerance
Dopaminergic stimulants
Harm Potential
Addiction & Dependence
Psychological
Moderate4-FMA is described as having moderate addictive potential and high abuse liability, and psychological dependence may develop in some users.citation needed Reports also identify compulsive redosing as a notable cognitive effect.
Physical
Cravings and withdrawal effects may occur if chronic users suddenly stop usage, though specific physical withdrawal symptoms have not been characterized in the available literature.
Toxicity
Cardiovascular
4-FMA is reported to produce more cardiovascular side effects than similar fluorinated amphetamines; serious cardio- and cerebrovascular complications have been documented including arrhythmias, conduction disturbances, and acute cardiac failure, typically in the context of higher doses or pre-existing cardiovascular conditions.citation needed
Central Nervous System
4-FMA may produce damage to the brain and carries increased risks for neurotoxicity; however, the actual extent of this risk and whether it causes long-lasting serotonin depletion like some related compounds remains unstudied.
Nasal and Pharyngeal Mucosa
4-FMA is particularly caustic compared to other compounds and can cause chemical burns within the nasal passage and throat when insufflated.
Psychosis Risk
Abuse of amphetamine-class compounds at high dosages for prolonged periods can result in stimulant psychosis presenting with paranoia, hallucinations, or delusions.citation needed Approximately 5-15% of users who develop stimulant psychosis fail to recover completely. Psychosis very rarely arises from occasional or therapeutic use patterns.
History & Culture
4-Fluoromethamphetamine first emerged in documented form when it was detected in legal high products sold in Japanese markets in 2006. Japan subsequently moved to regulate the compound in 2008, prohibiting its sale and possession with intent to distribute while stopping short of criminalizing…
Legality
By Country
Illegal6
AustriaIllegal (NPSG)Controlled under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act).12 Possession, production, and sale are prohibited.
CanadaSchedule I (analogue)Controlled since 1996 as an analogue of methamphetamine.5 Falls under the Controlled Drugs and Substances Act with associated criminal penalties for possession, trafficking, and production.
FinlandIllegalValtioneuvoston asetus huumausaineina pidettävistä aineista, valmisteista ja kasveista (543/2008), current consolidated Finlex text, Annex IV (Liite IV), as amended by Government Decree 651/2026 (published 1 July 2026; effective 10 July 2026); Huumausainelaki (Narcotics Act) 373/2008, §§ 3 and 5; Rikoslaki (Criminal Code) 39/1889, Chapter 50, §§ 1, 2, 2a.613141516
Government Decree 651/2026 is the latest schedule amendment as of 2026-08-28 and states that it enters into force on 10 July 2026; its Annex IV retains the exact 4-FMA entry. Annex IV also covers chemically possible stereoisomers (unless specifically excluded), salts where salt formation is possible, and preparations containing listed substances. Finland's Narcotics Act § 3 defines a narcotic by reference to the 1961/1971 convention lists and other specified categories, with the Government decree supplying the detailed substance lists; § 5 prohibits unauthorized production, manufacture, import, export, transport, distribution, trade, handling, possession and use. Criminal Code Chapter 50 § 1 provides a fine or imprisonment up to two years for an ordinary narcotics offence, including possession or attempted acquisition and distribution; § 2 provides imprisonment of one to ten years for an aggravated offence when statutory aggravating conditions and overall seriousness are met; § 2a provides a fine or up to six months for illegal use or possession/acquisition of a small amount for personal use. These are statutory ranges, not a prediction of sentence in a particular case.
ItalySchedule IListed as a Schedule I controlled substance under Italian drug legislation.2 Production, sale, and possession are prohibited.
JapanIllegal指定薬物名称・構造式一覧（令和８年８月27日現在：2,484物質） [MHLW Designated Substance Names and Structural Formulas List, current 27 August 2026]34
The current MHLW list identifies 4-FMA as a designated drug, and MHLW expressly states that designated-drug possession and use, as well as purchase and receipt, have been prohibited since 1 April 2014. Ordinary possession and use are therefore prohibited, with no personal-possession exemption; any legally authorized statutory or medical context must be assessed separately under the applicable PMD Act provisions.
United KingdomClass AControlled under the Misuse of Drugs Act 1971, added through the 1977 amendment covering fluorinated amphetamine derivatives.24 Class A designation carries the most severe penalties including up to 7 years imprisonment for possession.
Controlled / restricted5
AustraliaSchedule 9Prohibited substance under the Poisons Standard.18 This category applies to substances with abuse or misuse potential; manufacture, possession, sale, and use are meant to be legally barred except for health-authority-approved medical or scientific research, analysis, teaching, or training.
ChinaControlled substanceDesignated a controlled substance as of October 2015 under national drug control legislation.1
GermanyAnlage II BtMGControlled under Schedule II of the Betäubungsmittelgesetz (Narcotics Act) since July 26, 2012.17 Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without license are prohibited.
New ZealandSchedule 3 (Class C)Controlled as an amphetamine analogue under the Misuse of Drugs Act.19 Schedule 3 substances carry penalties for possession, supply, and manufacture.
SwitzerlandRestrictedBetäubungsmittelverzeichnisverordnung (BetmVV-EDI; SR 812.121.11), Annex 6 Verzeichnis e item 16 (consolidated standing 13 March 2026); Betäubungsmittelkontrollverordnung (BetmKV; SR 812.121.1), Articles 3(2)(e), 5(2) and 11(1); Betäubungsmittelgesetz (BetmG; SR 812.121), Article 7(1)202122
The exact substance is expressly named as item 16 in the current consolidated BetmVV-EDI Annex 6 Verzeichnis e. That category is controlled under BetmVV-EDI Articles 1(2)(a) and 2(2), with the Article 7 BetmG authorization framework and EDI permit requirement described by BetmKV. Verzeichnis e is distinct from Verzeichnis d and controls 4-FMA through authorization rather than categorically prohibiting every act involving it.
Not scheduled2
United StatesUnscheduled (Analogue Act applies)Not specifically scheduled at the federal level. However, as a structural analogue of methamphetamine, sale or possession could be prosecuted under the Federal Analogue Act when intended for human consumption.23
FranceNot scheduledFrench Public Health Code article L. 5132-7 classification framework; ANSM consolidated List of Substances Classified as Narcotics, last updated 26 June 2026; ANSM consolidated List of Psychotropic Substances, last updated 3 July 2026; Code de la santé publique article L. 3421-1 as summarized by Service-Public.fr.67891011
The ANSM narcotics list dated 26 June 2026 contains entries for 4-fluoroamphétamine/4-FA and for Méthamphétamine et son racémate, but no 4-FMA, 4-fluorométhamphétamine, fluoromethamphetamine or CAS 351-03-1 entry. Its scope clauses cover the named substances and specified isomers, esters, ethers, salts and preparations; 4-FMA is a para-fluoro N-methyl derivative, not an isomer of methamphetamine, and the list contains no general amphetamine-analogue clause that would itself capture it. The ANSM psychotropics list dated 3 July 2026 likewise contains no 4-FMA or 4-fluoromethamphetamine entry. MILDECA's December 2025 government guide explains that some new synthetic substances are not yet classified as narcotics and consequently escape narcotics legislation while awaiting identification/classification. Under the narcotics/psychotropics schedules, 4-FMA is unscheduled; this is not an affirmative declaration that every possession, import, sale or preparation is lawful under every French regime. Service-Public.fr states that use of substances classified as narcotics carries a 500 EUR fixed fine (400 EUR reduced, 1,000 EUR increased) and, in court, up to one year imprisonment and 3,750 EUR fine. Because 4-FMA is absent from the current schedules, those narcotics-use penalties do not apply to it solely by analogy; other rules (for example medicines, customs, product-safety or a later ANSM classification) are outside this schedule-based classification.
References
Source Pages
Citations
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- LStep 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 4-FMA article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
